SharePoint
A- A A+

About NCIS

Clinical and Treatment Outcomes

Clinical and Treatment Outcomes

​NCIS success rate for the Haematopoietic Stem Cell Transplant / Bone Marrow Transplant Programme is comparable to the international registry data at the Centre for International Blood & Marrow Transplant Research (CIBMTR) and the European Group for Blood and Marrow Transplant (EBMT).

​Type of transplant
​Diagnosis
​NCIS Success Rate
​International Registry Success Rate
​Reference
​Matched Sibling Donor (MSD) Transplant
​Acute Leukaemia
​~50% at 5 years (2005 - 2016)
​~50% at 5 years (2001 - 2018), CIBMTR
​Cheryl Lim, Koh LP et al. EBMT 2017
​Matched Unrelated (Volunteer) Donor (MUD) Transplant
​​Acute Leukaemia
​​~50% at 5 years (2005 - 2016)
​​~50% at 5 years (2001 - 2018), CIBMTR
​​Cheryl Lim, Koh LP et al. EBMT 2017
​Unrelated Umbilical Cord Blood (UCB) Transplant
​Haematological Cancers (Leukemia, Lymphoma, Myelodysplastic Syndromes)
​~50% at 3 years (2007 - 2019)
​~40% at 5 years (2005 - 2016), EBMT
​Ian Wu, Koh LP et al. ASH 2020. Ruggeri A, et al. Leukemia 2015.
​Sequential Transplant Using Matched Related/Unrelated Donor
​Haematological Cancers
​~60% at 3 years (2006 - 2020)
​~55% at 3 years (2007 - 2019) (EBMT)
​Chong LL, Koh LP, et al. ASH 2020. Malard F, et al. BBMT 2017

References:

  • Centre for International Blood & Marrow Transplant Research, www.cibmtr.org
  • European Group for Blood and Marrow Transplantation, www.ebmt.org
(Information is correct as at July 2022)